Access to patient portals increases the likelihood that patients with or at risk for cardiovascular disease will engage in shared decision-making.

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

The long-term incidence of MACE, VTE, and malignancies is low among patients with RA or UC receiving filgotinib, though a slight increase was observed among older patients.

For patients undergoing noncardiac surgery, neurocognitive outcomes do not differ with hypotension-avoidance and hypertension-avoidance strategies.

Both CPAP and tirzepatide are acceptable treatments for comorbid obesity and OSA, with providers favoring CPAP and patients preferring tirzepatide.

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced 24-hour systolic blood pressure in individuals with uncontrolled and treatment-resistant hypertension, according to ...

For patients with CKD and T2D, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone.

There is increased use of quadruple medical therapy among patients following implementation of an HF quality improvement initiative.

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

The cardiorespiratory effects of smoke fine particulate matter, a primary wildfire emission that can spike for months after a wildfire begins, can persist for months.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

A substantial number of US dementia cases could be eliminated by mitigating modifiable cardiometabolic risk factors, ...